Goldman Sachs Group Inc Bridge Bio Pharma, Inc. Call Options Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BBIO
# of Institutions
291Shares Held
171MCall Options Held
10.4MPut Options Held
2.37M-
Kohlberg Kravis Roberts & Co. L.P. New York, NY25.3MShares$582 Million35.94% of portfolio
-
Viking Global Investors LP25.1MShares$579 Million2.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.2MShares$327 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$287 Million0.01% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$140 Million63.58% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $3.42B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...